Entity

Time filter

Source Type

Ames, IA, United States

Mogler M.A.,Harrisvaccines, Inc. | Kamrud K.I.,Synthetic Genomics, Inc
Expert Review of Vaccines | Year: 2014

The advent of reverse genetic approaches to manipulate the genomes of both positive (+) and negative (-) sense RNA viruses allowed researchers to harness these genomes for basic research. Manipulation of positive sense RNA virus genomes occurred first largely because infectious RNA could be transcribed directly from cDNA versions of the RNA genomes. Manipulation of negative strand RNA virus genomes rapidly followed as more sophisticated approaches to provide RNA-dependent RNA polymerase complexes coupled with negative-strand RNA templates were developed. These advances have driven an explosion of RNA virus vaccine vector development. That is, development of approaches to exploit the basic replication and expression strategies of RNA viruses to produce vaccine antigens that have been engineered into their genomes. This study has led to significant preclinical testing of many RNA virus vectors against a wide range of pathogens as well as cancer targets. Multiple RNA virus vectors have advanced through preclinical testing to human clinical evaluation. This review will focus on RNA virus vectors designed to express heterologous genes that are packaged into viral particles and have progressed to clinical testing. © 2015 Informa UK, Ltd. Source


Patent
Harrisvaccines, Inc. | Date: 2011-10-19

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Grant
Agency: Department of Agriculture | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 460.00K | Year: 2011

Currently there are no truly effective interventions or therapeutic treatments for White spot syndrome virus (WSSV) in farmed shrimp. Current production practices focus on pathogen exclusion by stocking specific pathogen free (SPF) larvae, decontamination and filtration of water to prevent pathogen introduction, and strict biosecurity at hatcheries and grow out pond sites. This is extremely challenging due to the prevalence of WSSV in estuarine waters in shrimp producing areas, resulting in devastating financial losses, even in SPF populations. WSSV was first discovered in 1992 after several outbreaks of a high mortality disease occurred in shrimp farms in Taiwan. Within a decade it has spread throughout the world and is now endemic in most shrimp producing areas. WSSV has a wide host range of over 50 separate species including all penaeids and crayfish. In the United States, a 2007 APHIS study showed that 66% of tested samples were positive and it has been declared endemic by the state veterinarian and OIE in the Louisiana freshwater crayfish population. The combined economic impact of WSSV in farmed shrimp is tremendous. It is estimated that Asia alone has lost over $6 billion since 1992, and the Americas about $1-2 billion since WSSV introduction in 1999 with countries such as Ecuador showing the greatest economic impact. In addition to the tremendous economic effect on shrimp production, there is a rising concern for an introduction of WSSV into native crustacean species. Avenues exist for the introduction of WSSV into naive species such as reprocessing of frozen emergency harvested product or animal movement. In addition, the United States possesses over 350 of the estimated 500 species worldwide of crayfish species. In North America, 65 out of the estimated 400 resident species are endangered and half of these are listed as needing protection. The outcome of the proposed project would be the first effective commercially available vaccines that protect against disease caused by WSSV in shrimp. Harrisvaccines intends to market vaccine to be used in two different shrimp production settings. First, an injectable vaccine for adult breeding females will be targeted to SPF production companies and larger integrated intensive shrimp producers abroad who possess their own hatcheries for the purpose of restocking their ponds. The second would be an orally administered vaccine for post larvae (PL) shrimp that would aid in protection of the shrimp prior to entry into the ponds. This accomplishes disease prevention in the hatcheries as well as the ponds. The goal is to prevent disease that can cause increases in the variable costs of raising shrimp. In addition to the observable clinical signs of disease, WSSV is directly responsible for a reduction of feed conversion rates which result in increased feed costs and a reduction in harvest weight combined with 70-100% mortality. The costs associated with restocking ponds lost to disease add to this devastation. A vaccine against WSSV is undoubtedly a valuable insurance for the investment of shrimp rearing.


Patent
Harrisvaccines, Inc. | Date: 2013-01-08

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Patent
Harrisvaccines, Inc. | Date: 2014-07-23

Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.

Discover hidden collaborations